Alpine Immune Sciences to Present Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late Breaker Poster Session at American Society of Nephrology Kidney Week 2023
16 October 2023
The Company will host an investor event following the presentation after the close of market on Thursday, November 2nd
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the Company will present initial clinical data from RUBY-3, a phase 1b/2a study of povetacicept in autoimmune glomerulonephritis including IgA nephropathy, in a late breaking poster presentation at the American Society of Nephrology (ASN) Kidney Week, November 1-5, 2023 in Philadelphia, Pennsylvania. Following the poster presentation, the Company will host an investor event after the close of the market.
American Society of Nephrology – Kidney Week 2023
Date/Time: Thursday, November 2, 2023, 10:00 am – 12:00 pm ET
Poster Title: Povetacicept, an Enhanced Dual BAFF/APRIL Antagonist, in Autoantibody-Associated Glomerulonephritis (GN)
Poster Board Number: TH-PO1125
Session Name: Late-Breaking Posters
Location: Exhibit Hall, Pennsylvania Convention Center, Philadelphia
Presenter: James Tumlin, M.D., Professor of Medicine at Emory University School of Medicine, Founder and CEO of NephroNet Clinical Trials Consortium
Investor Event
Date/Time: Thursday, November 2, 2023, at 4:30 pm – 5:30 pm ET
Link to Webcast: https://bit.ly/48Gk8yH